Global Pneumococcal Vaccines Market Overview And Scope:
Global Pneumococcal Vaccines Market Size was estimated at USD 7208.84 million in 2022 and is projected to reach USD 7702.93 million by 2028, exhibiting a CAGR of 1.11% during the forecast period.
The Global Pneumococcal Vaccines Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Pneumococcal Vaccines utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Pfizer, Sanofi, GSK, Merck, Eli Lilly, AstraZeneca, Abera, S K Chemicals, Beijing Minhai Biotechnology, Baxter, Biken, Celgene Corporation, Panacea Biotec, Serum Institute of India, Genentech, Genocea Biosciences, ImmunoBiology, Lupin, Nuron Biotech, Biogen, Valneva Austria, Sinovac
Global Pneumococcal Vaccines Market Segmentation
By Type, Pneumococcal Vaccines market has been segmented into:PPSV 23
PCV 7/13
PCV 10
By Application, Pneumococcal Vaccines market has been segmented into:
For Infants
For Children (2-10)
For Person (10-64)
For The Old (Above 65)
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Pneumococcal Vaccines market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Pneumococcal Vaccines market.
Top Key Players Covered in Pneumococcal Vaccines market are:
Pfizer
Sanofi
GSK
Merck
Eli Lilly
AstraZeneca
Abera
S K Chemicals
Beijing Minhai Biotechnology
Baxter
Biken
Celgene Corporation
Panacea Biotec
Serum Institute of India
Genentech
Genocea Biosciences
ImmunoBiology
Lupin
Nuron Biotech
Biogen
Valneva Austria
Sinovac
Objective to buy this Report:
1. Pneumococcal Vaccines analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Pneumococcal Vaccines market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Pneumococcal Vaccines Market by Type
5.1 Pneumococcal Vaccines Market Overview Snapshot and Growth Engine
5.2 Pneumococcal Vaccines Market Overview
5.3 PPSV 23
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 PPSV 23: Geographic Segmentation
5.4 PCV 7/13
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 PCV 7/13: Geographic Segmentation
5.5 PCV 10
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 PCV 10: Geographic Segmentation
Chapter 6: Pneumococcal Vaccines Market by Application
6.1 Pneumococcal Vaccines Market Overview Snapshot and Growth Engine
6.2 Pneumococcal Vaccines Market Overview
6.3 For Infants
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 For Infants: Geographic Segmentation
6.4 For Children (2-10)
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 For Children (2-10): Geographic Segmentation
6.5 For Person (10-64)
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 For Person (10-64): Geographic Segmentation
6.6 For The Old (Above 65)
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 For The Old (Above 65): Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Pneumococcal Vaccines Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Pneumococcal Vaccines Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Pneumococcal Vaccines Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 PFIZER
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 SANOFI
7.4 GSK
7.5 MERCK
7.6 ELI LILLY
7.7 ASTRAZENECA
7.8 ABERA
7.9 S K CHEMICALS
7.10 BEIJING MINHAI BIOTECHNOLOGY
7.11 BAXTER
7.12 BIKEN
7.13 CELGENE CORPORATION
7.14 PANACEA BIOTEC
7.15 SERUM INSTITUTE OF INDIA
7.16 GENENTECH
7.17 GENOCEA BIOSCIENCES
7.18 IMMUNOBIOLOGY
7.19 LUPIN
7.20 NURON BIOTECH
7.21 BIOGEN
7.22 VALNEVA AUSTRIA
7.23 SINOVAC
Chapter 8: Global Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 PPSV 23
8.2.2 PCV 7/13
8.2.3 PCV 10
8.3 Historic and Forecasted Market Size By Application
8.3.1 For Infants
8.3.2 For Children (2-10)
8.3.3 For Person (10-64)
8.3.4 For The Old (Above 65)
Chapter 9: North America Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 PPSV 23
9.4.2 PCV 7/13
9.4.3 PCV 10
9.5 Historic and Forecasted Market Size By Application
9.5.1 For Infants
9.5.2 For Children (2-10)
9.5.3 For Person (10-64)
9.5.4 For The Old (Above 65)
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 PPSV 23
10.4.2 PCV 7/13
10.4.3 PCV 10
10.5 Historic and Forecasted Market Size By Application
10.5.1 For Infants
10.5.2 For Children (2-10)
10.5.3 For Person (10-64)
10.5.4 For The Old (Above 65)
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 PPSV 23
11.4.2 PCV 7/13
11.4.3 PCV 10
11.5 Historic and Forecasted Market Size By Application
11.5.1 For Infants
11.5.2 For Children (2-10)
11.5.3 For Person (10-64)
11.5.4 For The Old (Above 65)
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 PPSV 23
12.4.2 PCV 7/13
12.4.3 PCV 10
12.5 Historic and Forecasted Market Size By Application
12.5.1 For Infants
12.5.2 For Children (2-10)
12.5.3 For Person (10-64)
12.5.4 For The Old (Above 65)
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 PPSV 23
13.4.2 PCV 7/13
13.4.3 PCV 10
13.5 Historic and Forecasted Market Size By Application
13.5.1 For Infants
13.5.2 For Children (2-10)
13.5.3 For Person (10-64)
13.5.4 For The Old (Above 65)
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 PPSV 23
14.4.2 PCV 7/13
14.4.3 PCV 10
14.5 Historic and Forecasted Market Size By Application
14.5.1 For Infants
14.5.2 For Children (2-10)
14.5.3 For Person (10-64)
14.5.4 For The Old (Above 65)
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Pneumococcal Vaccines Scope:
|
Report Data
|
Pneumococcal Vaccines Market
|
|
Pneumococcal Vaccines Market Size in 2025
|
USD XX million
|
|
Pneumococcal Vaccines CAGR 2025 - 2032
|
XX%
|
|
Pneumococcal Vaccines Base Year
|
2024
|
|
Pneumococcal Vaccines Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Pfizer, Sanofi, GSK, Merck, Eli Lilly, AstraZeneca, Abera, S K Chemicals, Beijing Minhai Biotechnology, Baxter, Biken, Celgene Corporation, Panacea Biotec, Serum Institute of India, Genentech, Genocea Biosciences, ImmunoBiology, Lupin, Nuron Biotech, Biogen, Valneva Austria, Sinovac.
|
|
Key Segments
|
By Type
PPSV 23
PCV 7/13
PCV 10
By Applications
For Infants
For Children (2-10)
For Person (10-64)
For The Old (Above 65)
|
